Insurers are increasingly denying prescriptions of direct-acting antiviral (DAA) drugs for hepatitis C virus treatment, according to a study published online June 7 in Open Forum Infectious Diseases.
The project, conducted in collaboration with the Arkhangai Province Health Department in Mongolia has managed to cure and control liver disease caused by viral HCV amongst the population in Arkhangai.